Simpler
Bypass Surgery Makes a Difference
Minimally
invasive technique more effective than other procedures, study finds
The
increasing availability of a surgical technique that uses a small incision
for bypass surgery is making a difference.
The
technique, minimally invasive bypass surgery, now is preferable for
many patients who otherwise would be treated with the artery-opening
procedure called angioplasty, says a report in a recent issue of
the New England Journal of Medicine. Angioplasty is
a procedure in which thin balloons and other devices are threaded into
a coronary artery and inflated to remove plaque that has blocked blood
flow.
With
the minimally invasive technique, the surgeon can do a bypass procedure
through an incision as small as 4 inches, rather than sawing open the
breastbone, as is done in conventional bypass surgery. Minimally invasive
surgery can be done on the beating heart; conventional surgery requires
the heart be stopped and the patient put on a heart-lung machine.
In
the latest study, cardiologists at the University of Leipzig Heart Center
in Germany compared the outcome of the minimally invasive technique
to angioplasty followed by the implantation of a stent, a tube designed
to keep the blood vessel open. Included in the study were 220 patients
with blockage of a major heart vessel, the left anterior descending
coronary artery.
This
is "a very important coronary artery, and one that is at high risk for
restenosis," says lead author Dr. Gerhard Schuler, a professor of medicine
at Leipzig. Restenosis is a potentially life-threatening closing of
the artery after its blood flow has been restored by angioplasty or
a bypass.
The
study was done because balloon angioplasty followed by stenting has
become the standard procedure for the condition, but no studies have
compared stenting with minimally invasive bypass, Schuler says. In the
study, half the patients had stenting, the other half had minimally
invasive bypass surgery.
Overall,
the results favored bypass surgery, Schuler says. The incidence of complications
immediately after the procedure was higher for the surgery patients,
but after six months only 21 percent of the bypass patients had angina—chest
pain caused by artery blockage—compared with 38 percent of
the angioplasty-stent patients. Restenosis occurred in 29 percent of
the stent patients, compared with 5 percent of the bypass patients.
And 31 percent of the stent patients had a major cardiac event such
as a heart attack, compared to 16 percent of the bypass patients.
Those
results indicate that bypass surgery is a preferable treatment, but
only if it is done with the minimally invasive method, in which "surgical
trauma is much less severe and the hospital stay is shorter," Schuler
says.
Other
medical conditions influence the decision, he adds: "For patients at
high risk of stenosis, such as those with diabetes, we feel that they
should undergo bypass surgery, conventional or minimally invasive."
Also,
the arrival of a new generation of stents that are coated with drugs
designed to prevent the artery from closing might make a difference,
says an accompanying editorial by Dr. Thomas E. MacGillivray and Dr.
Gus J. Vlahakas, both of Massachusetts General Hospital.
"Recent
studies using drug-coated stents suggest that these devices reduce...recurrent
stenosis, although long-term data are not yet available," they write.
Always
consult your physician for more information.
|
September
2002
Minimally
Invasive Technique Shown More Effective Than Other Procedures, Study
Finds
The
Tale of Two Heart Drugs
Online
Resources
Find
a St. John's Mercy Physician
In
Other News About Your Heart:
The
Tale of Two Heart Drugs
A
study in a recent issue of The Lancet clarifies
the differences between two similar drugs given to people who have
angioplasty to treat narrowed coronary arteries.
The
drugs, tirofiban and abciximab, are used to reduce the clumping
together of platelets in the blood, something that can cause complications
during procedures to open narrowed arteries.
This
study looked at outcomes for 4,809 people six months after they
had coronary-artery angioplasty with stent placement. They found
that 14.8 percent of the people who took tirofiban died, had a heart
attack or had repeat surgery within those six months, compared to
14.3 percent of the people who took abciximab.
The
study concludes that both drugs are similar in terms of preventing
these long-term events. An earlier study by the same researchers
showed that abciximab was significantly better than tirofiban at
preventing death, heart attacks, and repeat surgery within 30 days
after people had angioplasty for narrowed coronary arteries.
"As
studied, abciximab was more protective against a heart attack occurring
during, or immediately following angioplasty. Yet the two drugs
were associated with similarly low rates of death and renarrowing
of the heart's arteries at six months. Our conclusion is that, while
the more expensive drug (abciximab) is better 'up front', it provides
little long-term advantage compared with tirofiban," says the study's
lead author, Dr. David Moliterno of the Cleveland Clinic Foundation.
Always
consult your physician for more information.
Online
Resources
American
Heart Association
The
Lancet
National
Heart, Lung, and Blood Institute (NHLBI)
New
England Journal of Medicine
|